GERUSSI, ALESSIO
 Distribuzione geografica
Continente #
NA - Nord America 3.787
EU - Europa 2.558
AS - Asia 415
AF - Africa 8
SA - Sud America 8
Totale 6.776
Nazione #
US - Stati Uniti d'America 3.772
DE - Germania 910
IT - Italia 597
SE - Svezia 389
IE - Irlanda 333
CN - Cina 160
GB - Regno Unito 146
HK - Hong Kong 139
BE - Belgio 41
IN - India 38
FR - Francia 25
FI - Finlandia 22
VN - Vietnam 22
NL - Olanda 19
UA - Ucraina 18
AT - Austria 16
DK - Danimarca 16
MY - Malesia 16
CA - Canada 15
IL - Israele 9
TR - Turchia 7
BR - Brasile 6
RU - Federazione Russa 6
IR - Iran 5
MM - Myanmar 4
PL - Polonia 4
ES - Italia 3
JP - Giappone 3
PK - Pakistan 3
RO - Romania 3
SC - Seychelles 3
TW - Taiwan 3
CH - Svizzera 2
EG - Egitto 2
GH - Ghana 2
GR - Grecia 2
SK - Slovacchia (Repubblica Slovacca) 2
AR - Argentina 1
EC - Ecuador 1
EE - Estonia 1
IQ - Iraq 1
KR - Corea 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
MN - Mongolia 1
PH - Filippine 1
PT - Portogallo 1
SG - Singapore 1
ZA - Sudafrica 1
Totale 6.776
Città #
Ann Arbor 1.272
Frankfurt am Main 859
Fairfield 361
Dublin 318
Chandler 292
Wilmington 265
Milan 200
Ashburn 178
Woodbridge 166
New York 145
Hong Kong 133
Houston 129
Seattle 126
Cambridge 118
Princeton 98
London 76
Dearborn 66
Shanghai 50
Altamura 46
Lawrence 46
Brussels 40
Boardman 31
San Diego 26
Rome 25
Chicago 24
Beijing 20
Pune 20
Jacksonville 19
Helsinki 18
Monza 16
Penang 16
Guangzhou 14
Nanjing 13
Turin 12
Vienna 12
Mumbai 11
Andover 10
Lissone 10
Fremont 9
Dong Ket 8
Padova 8
Bologna 7
Modena 7
Toronto 7
Central 6
Jinan 6
Kocaeli 6
Somma Vesuviana 6
Cagliari 5
Genoa 5
Hangzhou 5
Huizen 5
Marietta 5
Naples 5
Sacramento 5
Shenyang 5
Appiano Gentile 4
Atlanta 4
Council Bluffs 4
Florence 4
Groningen 4
Hanover 4
Hebei 4
Hefei 4
Lappeenranta 4
Meda 4
Norwalk 4
Paris 4
Rimini 4
São Paulo 4
Udine 4
Zhengzhou 4
Bergamo 3
Brescia 3
Changsha 3
Chioggia 3
Conversano 3
Cossato 3
Falls Church 3
Gdansk 3
Haikou 3
Kilburn 3
Magdeburg 3
Montesilvano Marina 3
New Taipei 3
Siena 3
Terni 3
Tianjin 3
Utrecht 3
Vigevano 3
Washington 3
Xian 3
Accra 2
Acquaviva delle Fonti 2
Aga 2
Agrate Brianza 2
Alzano Lombardo 2
Amsterdam 2
Athens 2
Baniapur 2
Totale 5.531
Nome #
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 426
Quality of life in patients with primary biliary cholangitis: a cross-geographical comparison 210
Better end points needed in primary sclerosing cholangitis trials 204
Novel biomarkers for primary biliary cholangitis to improve diagnosis and understand underlying regulatory mechanisms 192
FRI-006-Soluble CD163 and mannose receptor as markers of liver disease severity and long term prognosis in patients with primary biliary cholangitis 186
FRI-008-Incidence, prevalence and mortality of primary sclerosing cholangitis in Italy: A population-based study 186
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 180
THU-010-Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis 172
Precision medicine in primary biliary cholangitis 167
Accuracy of Liver Stiffness Measurement in assessing liver fibrosis in naïve patients with Primary Biliary Cholangitis 160
Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma 158
Additive beneficial effects of Fibrates combined with Obeticholic acid in the treatment of patients with Primary Biliary Cholangitis and inadequate response to second-line therapy: data from the Italian PBC Study Group 155
FRI-011-Ductular reaction, intermediate hepatocites and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 154
Novel insights in primary biliary cholangitis (PBC) epidemiology using administrative records 151
Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies 150
Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naïve patients with Primary Biliary Cholangitis: a dual cut-off approach 146
A National Hospital‐Based Study of Hospitalized Patients With Primary Biliary Cholangitis 144
Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis 141
New Therapeutic Targets in Autoimmune Cholangiopathies 140
Detailed stratified GWAS analysis for severe COVID-19 in four European populations 135
Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients 134
Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets 134
Association Between Black Race and Presentation and Liver-Related Outcomes of Patients With Autoimmune Hepatitis 124
Immune-mediated drug-induced liver injury: Immunogenetics and experimental models 124
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 124
Machine learning in primary biliary cholangitis: A novel approach for risk stratification 124
Mapping the human genetic architecture of COVID-19 117
Support of precision medicine through risk-stratification in autoimmune liver diseases - histology, scoring systems, and non-invasive markers 111
The immunobiology of female predominance in primary biliary cholangitis 110
Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe 107
The application of artificial intelligence in hepatology: A systematic review 106
Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study 103
Risk stratification in primary sclerosing cholangitis 102
Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis 96
Cost of illness of Primary Biliary Cholangitis - a population-based study 93
The prognosis following bacterascites is as poor as spontaneous bacterial peritonitis 89
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 86
Gender differences in liver disease and the drug-dose gender gap 85
The role of ethnicity in autoimmune hepatitis 85
Normalization of serum immunoglobulin G levels is associated with improved transplant-free survival in patients with autoimmune hepatitis 83
DISSECTING THE GENETIC ARCHITECTURE OF AUTOIMMUNITY: A SPOTLIGHT ON PRIMARY BILIARY CHOLANGITIS 77
Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis 76
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 73
Elevated baseline igg is a risk factor for on-treatment flares of autoimmune hepatitis in patients in biochemical remission 73
Corrigendum to: “An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs” [J Hepatol 75 (2021) 572-581, (S0168827821003342), (10.1016/j.jhep.2021.04.055)] 70
Primary sclerosing cholangitis: Burden of disease and mortality using data from the national rare diseases registry in Italy 70
Identifying Racial Disparities in Primary Biliary Cholangitis Patients: A Step Toward Achieving Equitable Outcomes Among All 67
Case Report: Hypomorphic Function and Somatic Reversion in DOCK8 Deficiency in One Patient With Two Novel Variants and Sclerosing Cholangitis 65
Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group 62
Artificial intelligence for precision medicine in autoimmune liver disease 53
Real-world experience with obeticholic acid in patients with primary biliary cholangitis 53
A second update on mapping the human genetic architecture of COVID-19 51
Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis 50
Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055)) 49
Role of ductular reaction and ductular–canalicular junctions in identifying severe primary biliary cholangitis 48
Editorial: liver transplantation for primary biliary cholangitis–the need for timely and more effective treatments 46
The Role of Macrophages in Liver Fibrosis: New Therapeutic Opportunities 45
SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis 43
Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis 42
Anti-gp210 and other anti-nuclear pore complex autoantibodies in primary biliary cholangitis: What we know and what we should know 35
Genetics of Primary Biliary Cholangitis 34
Artificial Intelligence and liver: Opportunities and barriers 33
Bacterascites confers poor patient prognosis beyond MELD prediction 32
X marks the spot in autoimmunity 31
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 29
The Role of Epigenetics in Primary Biliary Cholangitis 29
The genetic architecture of primary biliary cholangitis 29
LLM-PBC: Logic Learning Machine-Based Explainable Rules Accurately Stratify the Genetic Risk of Primary Biliary Cholangitis 27
GWAS and autoimmunity: What have we learned and what next 26
New insights on the role of human leukocyte antigen complex in primary biliary cholangitis 25
Open challenges in the management of autoimmune hepatitis 22
Primary Sclerosing Cholangitis 18
Genetics of Autoimmune Liver Diseases 14
MEDTEC students against coronavirus: Investigating the role of hemostatic genes in the predisposition to COVID-19 severity 13
Ductular reaction, intermediate hepatocytes and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 3
Totale 7.207
Categoria #
all - tutte 24.070
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.070


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201975 0 0 0 0 0 0 0 0 14 14 21 26
2019/20201.074 20 142 42 115 105 117 142 109 115 92 52 23
2020/20211.525 34 29 276 66 122 205 170 223 102 85 119 94
2021/20221.051 107 104 160 108 79 61 43 69 48 25 85 162
2022/20232.126 172 440 148 141 236 245 156 134 156 110 117 71
2023/20241.338 88 93 108 189 212 328 207 37 76 0 0 0
Totale 7.207